Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287546 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT01287546 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 117 participants.
The verdict
NCT01287546, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
The objective of this study is to determine a recommended Phase 2 dose range of LY2875358 that may be safely administered to participants with advanced cancer. In Part A and Part A2 of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib will be evaluated for safety and tolerability, respectively. Part B is a dose-confirmation segment for LY2875358 therapy in 5 different types of cancer: nonsquamous non-small cell lung cancer (NSCLC), castrate resistant prostate cancer (CRPC) with bone metastases, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), or uveal melanoma with liver metastases, and for LY2875358 in combination with trametinib in participants with uveal melanoma with liver metastases.
Interventions
- DRUG LY2875358
- DRUG LY2875358 + erlotinib
- DRUG LY2875358 at Part A highest dose
- DRUG LY2875358 at Part A highest dose + trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2010-04-13 |
| Est. Completion | 2016-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287546
The ClinicalTrials.gov registry entry for NCT01287546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LY2875358 is the first listed.
NCT01287546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287546 about?
NCT01287546 is a clinical study titled "A Study of LY2875358 in Participants With Advanced Cancer". The objective of this study is to determine a recommended Phase 2 dose range of LY2875358 that may be safely administered to participants with advanced cancer. In Part A and Part A2 of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib will be evaluated for sa...
What is the current status of trial NCT01287546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2010-04-13. Estimated completion is 2016-10-26.
What interventions are being tested in trial NCT01287546?
The interventions under investigation include: LY2875358 (DRUG), LY2875358 + erlotinib (DRUG), LY2875358 at Part A highest dose (DRUG), LY2875358 at Part A highest dose + trametinib (DRUG).
Who is sponsoring clinical trial NCT01287546?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.